Bio-Path Holdings Reports $270,000 Net Loss in Q1 2026, Pauses Clinical Trials

Bio-Path Holdings, Inc. reported a net loss of $270,000 for the first quarter of 2026, a significant reduction from the $2.9 million loss recorded in the same period of 2025. The company did not generate any revenue during this quarter, consistent with the previous year. Operating expenses decreased to $297,000, down from $3.2 million in the prior year, primarily due to reduced research and development costs, which fell to $38,000 from $1.98 million, as the company paused its clinical trials amid cash flow constraints. General and administrative expenses also decreased to $259,000 from $1.26 million, reflecting a reduction in salaries and other overhead costs.

As of March 31, 2026, Bio-Path's total assets were $677,000, slightly down from $678,000 at the end of 2025. Current liabilities increased to $9.15 million from $8.89 million, driven by higher accounts payable, which rose to $5.16 million from $4.91 million. The company’s accumulated deficit reached $126.4 million, up from $126.2 million at the end of the previous fiscal year. Shareholders' equity showed a deficit of $8.49 million, compared to a deficit of $8.22 million at the end of 2025.

Strategically, Bio-Path has been focusing on its drug development pipeline, which includes four candidates targeting various cancer indications and obesity. The company has paused its clinical trials for its lead candidate, prexigebersen, due to financial constraints. In January 2026, Bio-Path issued 51 shares of Series S Preferred stock to facilitate restructuring efforts. The company also engaged Steel Giants Advisors LLC for operational restructuring and capital raising efforts.

Looking ahead, Bio-Path Holdings anticipates continued significant operating losses as it seeks to resume clinical trials and advance its drug candidates. The company has indicated that it will require substantial additional capital to fund its operations and meet its obligations over the next 12 months. As of the end of March 2026, the company had only $12,000 in cash, raising concerns about its ability to continue as a going concern without securing further funding. The management has expressed uncertainty regarding its ability to raise additional capital on favorable terms, which could impact its operational plans and future prospects.